Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Neil L Berinstein, MD, Nancy M Pennell, BSc, Rashmi Weerasinghe, Matthew C. Cheung, MD SM, FRCPC, Eugenia Piliotis, MD FRCP, MD, Kevin R Imrie, MD, Mary-Anne Cussen, Rena Buckstein, MD, Zeina Ghorab, Ellen Miles, Marciano D. Reis, MD

Blood (2016) 128 (22): 1794.

https://doi.org/10.1182/blood.V128.22.1794.1794

Published: 2016

Journal Articles

Assessment of Value Using the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) Frameworks for Novel Therapies for the Hematologic Malignancies

Matthew C Cheung, MD SM, FRCPC, Sierra Cheng, Erica McDonald, Vanessa Arciero, Mahin Qureshi, Kelvin Chan

Blood (2016) 128 (22): 3578.

https://doi.org/10.1182/blood.V128.22.3578.3578

Published: 2016

Journal Articles

Predictors for ICU Admission and Clinical Outcomes of Malignant Hematology Patients Admitted to Critical Care Units

Daniel Jacobson, BSc. (C), Nicholas Chiu, MD(C), Matthew C. Cheung, MD SM, FRCPC, Robert Fowler, MD MDM, M.Sc., Rena Buckstein, MD

Blood (2016) 128 (22): 3595.

https://doi.org/10.1182/blood.V128.22.3595.3595

Published: 2016

Journal Articles

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Tanya Skamene, MD, Wenyu Jiang, PhD, Ralph M. Meyer, MD, Michael Crump, MD, John Kuruvilla, MD, C. Tom Kouroukis, MD MSc, FRCPC, Stefano Luminari, Stephen Couban, MD, Matthew C. Cheung, MD SM, FRCPC, David A Rizzieri, MD, Peter G Bardy, MBBS, FRACP, FRCPA, Joseph Pater, MD MSc, Marina S. Djurfeldt, MSc, Lois E. Shepherd, MD, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 690.

https://doi.org/10.1182/blood.V128.22.690.690

Published: 2016

Journal Articles

Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Long-Term Remission

Matthew C Cheung, MD SM, FRCPC, Nicole Mittmann, PhD, Craig Earle, MD MSc., Farah Rahman, Ning Liu, Simron Singh, MD MPH, FRCPC

Blood (2016) 128 (22): 692.

https://doi.org/10.1182/blood.V128.22.692.692

Published: 2016

Journal Articles

Azacitidine Use in the Real World Does Not Replicate AZA-001 Results in Higher Risk MDS/Low Blast Count AML: An Audit of 1101 Patients in the Cancer Care Ontario Registry

Lee Mozessohn, MD FRCPC, Matthew C. Cheung, MD SM, FRCPC, Saber Fallahpour, PhD, Tripat Gill, MSc PH, Asmaa Maloul, PhD, Liying Zhang, PhD, Olivia Lau, Rena Buckstein, MD

Blood (2016) 128 (22): 4338.

https://doi.org/10.1182/blood.V128.22.4338.4338

Published: 2016

Journal Articles

Publication Patterns of Cancer Cost-Effectiveness Studies Presented at the American Society of Hematology: Timeliness of Publication, Quality and Possible Bias.

Lee Mozessohn, MD, Kelvin KW Chan, MD, MSc, FRCPC, Matthew C Cheung, MD, SM, FRCPC

Blood (2010) 116 (21): 3816.

https://doi.org/10.1182/blood.V116.21.3816.3816

Published: 2010

NARROW

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Assessment of Value Using the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) Frameworks for Novel Therapies for the Hematologic Malignancies

Predictors for ICU Admission and Clinical Outcomes of Malignant Hematology Patients Admitted to Critical Care Units

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Long-Term Remission

Azacitidine Use in the Real World Does Not Replicate AZA-001 Results in Higher Risk MDS/Low Blast Count AML: An Audit of 1101 Patients in the Cancer Care Ontario Registry

Publication Patterns of Cancer Cost-Effectiveness Studies Presented at the American Society of Hematology: Timeliness of Publication, Quality and Possible Bias.

Email alerts

ASH Publications

American Society of Hematology

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Assessment of Value Using the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) Frameworks for Novel Therapies for the Hematologic Malignancies

Predictors for ICU Admission and Clinical Outcomes of Malignant Hematology Patients Admitted to Critical Care Units

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Long-Term Remission

Azacitidine Use in the Real World Does Not Replicate AZA-001 Results in Higher Risk MDS/Low Blast Count AML: An Audit of 1101 Patients in the Cancer Care Ontario Registry

Publication Patterns of Cancer Cost-Effectiveness Studies Presented at the American Society of Hematology: Timeliness of Publication, Quality and Possible Bias.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only